Recently, it has been reported that 
Introduction
Epidemiological studies have been instrumental in demonstrating an inverse relationship between vitamin D intake, sunlight exposure and risk for colon cancer (1) . Recently, a metaanalysis conducted by Gorham et al (2) examined the dose response relationship between vitamin D intake or serum 25(OH)D 3 and risk for colon cancer. Dose-gradient curves generated from eighteen of the forty-four existing observational studies demonstrated that individuals with ≥ 1000 IU/day oral vitamin D or ≥ 33 ng/ml serum 25(OH)D 3 had 50% lower risk for developing colon cancer compared to reference values (2) .
In spite of the extensive evidence demonstrating the anti-cancer activity of 1,25(OH) 2 D 3 in colon cancer, its clinical use is limited by its susceptibility to cause hypercalcemia. Hence, in order to retain the efficacy but reduce its toxicity numerous analogs have been synthesized and evaluated for the prevention and treatment of colon cancer. Until recently, little attention was given to 25(OH)D 3 as a potential chemopreventive agent since it was commonly believed that the enzyme 1α(OH)ase was selectively present in the kidney. The existence of 1α(OH)ase in colon epithelial cells has led to interest in the potential use of this non-toxic prohormone, 25 (OH)D 3 , as an effective chemoprotective agent against colon cancer (3, 4, 5) . The possibility of using The 25(OH)D 3 as a chemopreventive and/or chemotherapeutic agent has been further strengthen by in vitro studies which have demonstrated that cells containing 1α(OH)ase are able to convert 25(OH)D 3 into 1,25(OH) 2 D 3 (6,7). For example, Bareis et al (7) demonstrated that the Caco-2 colon cancer cells, which is a moderately differentiated colon cancer cell line, are able to produce 1,25(OH) 2 D 3 from the pro-hormone. Here we report that normal, aberrant crypt foci (ACF) and malignant human cancer samples express VDR and 1α(OH)ase and that 25(OH)D 3 is efficacious as an antiproliferative agent in human colon cancer cells.
Materials and Methods

Tumor Specimens and Histological Grading
Colon cancers were randomly selected from the University of Illinois at Chicago Gastrointestinal Tumor Bank. The University of Illinois at Chicago and Veterans Administration Institutional Review Boards approved use of these tissues. Differentiation was assessed as previously described (8).
Human Colon Cancer Cell lines
The HT-29, Caco-2 and SW480 cell lines were obtained from American Type Culture Collection (Manassas, VA) and maintained in RPMI 1640 media (Life Technologies, Inc., Grand Island, NY) with 10% fetal bovine serum, 2 mM L-glutamine and 1% antibioticantimycotic solution and kept in a 37°C humidified atmosphere of 5% CO 2.
Analysis of Cell Proliferation
For determination of proliferation, HT-29 cells were seeded at a density of 2 × 10 4 per well in a 12-well cell culture plate and allowed to adhere overnight. After incubation with or without 25(OH)D 3 for the appropriate times, cells were detached with trypsin and cell number was determined by the Coulter counter.
FACS Analysis
Colon cancer cells were seeded at a density of 5.0 × 10 5 in 25cm 2 flasks and allowed to adhere for 24 h. Following treatment with or without 1.0 μM 25(OH)D 3 for 48 h, they were harvested with trypsin and washed with PBS. The samples were then stained with propidium iodide using the detergent-trypsin method described by Vindelov (9).
Measurement of Apoptosis
Cells undergoing apoptosis were evaluated using the In Situ Cell Death Detection Kit (Roche, Indianapolis, IN). A quantitative assessment was made by determining the percentage of apoptotic cells.
Western Blot analysis
Treated and untreated cells were lysed in freshly prepared extraction buffer. Protein concentration was determined using a modified Lowry method (Bio Rad, Hercules, CA). Samples were then separated on 10% polyacrylamide gels and transferred to nitrocellulose membranes. The membranes were blocked and then incubated with appropriate primary and secondary antibodies. Anti-VDR antibody was from Neomarkers (Freemont, CA), sheep Antimurine 25-hydroxyvitamin D3-1α-hydroxylase antibody was from The Binding Site (San Diego, CA). The chemiluminescence reaction was performed using the ECL system. Bands of interest were compared to that of actin and relative intensity ratios were calculated.
Immunofluorescence studies
SW480 cells were seeded on cover slips and allowed to adhere overnight. After incubation with or without 25(OH)D 3 (1 μM) for 24 h, the cells were fixed in buffered formalin, washed with PBST (PBS containing 0.1% Tween 20), permeabilized in 0.2% Triton X-100/PBS, blocked with 1% BSA, and then incubated with anti-VDR rat monoclonal antibody (1:200) for 1 h at RT. Cells were washed and incubated with TRIC-labeled anti-rat secondary antibody for 1h. After staining nuclei with DAPI, cells were visualized using the Olympus BX51 microscope. Tissues were sectioned (4 μm thick) and processed for immunohistochemistry as previously described (10).
Results
Expression of 1 α(OH)ase and VDR in Human colon tissue and cancer cells
The expression patterns of VDR and 1α(OH)ase were evaluated in human colon tissues. As shown in Fig 1A- E, 1α(OH)ase showed consistently strong expression in normal, premalignant (ACF) and malignant colonic epithelial cells, irrespective of tumor cell differentiation. In contrast, minimal VDR expression was observed in normal colonic epithelial cells, with the expression localized predominantly in the nucleus (Fig 1F) . Samples from ACFs revealed that the amount of VDR is significantly higher than that of adjacent normal tissue. Moreover, with malignant transformation, total cellular VDR expression increased markedly and was especially high in well-differentiated tumors (Fig 1H-I ) but then decreased with tumor cell dedifferentiation (Fig 1J) . Furthermore, these data suggest that 1α(OH)ase (Fig 1B) and VDR (Fig 1G) Fig 2B) were significantly increased following treatment with 25(OH)D 3 and 1α,25 (OH) 2 D 3 by 40 and 48%, respectively. Treatment with the cholecalicerfol (negative control) had no effect on the expression levels of 1α(OH)ase (Fig 2A) and showed only a marginal increase in the levels of VDR (Fig 2B) .
In addition to HT29 cells, we evaluated the effects of 25(OH)D 3 on SW480 colon cancer cells. The SW480 cell line was selected for this study since it is one of the best characterized human colon cancer cell lines, moreover it is widely used as a model system for vitamin D compounds, and is shown to have both VDR negative [VDR(-)] and VDR positive [VDR(+)] subpopulations (i.e., VDR(+) flat, polygonal and adherent line; and VDR(-) rounded, refractile, and less adherent) (11) . For these experiments, SW480 cells were plated on cover slips and treated with or without 25(OH)D 3 (1 μM) for 24, 48 or 72 h. At the appropriate time points, cells were fixed and immunofluorescence was completed as described in the materials and methods section. As shown in Fig 2C, 
The pro-hormone 25-hydroxyvitamin D 3 exerts anti-proliferative effects on human colon cancer cells
The anti-proliferative effects of 25(OH)D 3 were investigating using the HT-29 cells. For these studies, cells were plated, allowed to adhere for 24 h prior to treatment with the different vitamin D compounds. As shown in Fig 3, 
Discussion
Vitamin D3 is biologically inert and requires successive hydroxylations by mitochondrial P450 enzymes present in the liver and kidney to form the biologically active hormone 1α,25 (OH) 2 D 3 . The final step in metabolism is the conversion of prohormone 25(OH)D 3 to the active metabolite and hormone 1α,25(OH) 2 D 3 by 1α(OH)ase. Due to the hypercalcemic nature of 1α,25(OH) 2 D 3 , many relatively non-calcemic analogs of vitamin D have been synthesized and evaluated for their efficacy as anti-cancer agents. Ideally, the prohormone 25(OH)D 3 , which is naturally occurring and non-toxic could be developed, however due to the traditional concept of renal hydroxylation of the prohormone, until recently enthusiasm for establishing it as a cancer chemoprotective agent had been non-significant. In recent years, the expression of 1α (OH)ase, the enzyme that catalyzes this conversion, has been reported in several extra-renal tissues, including the pancreas, prostate, and colon (12) leading to the hypothesis that 25(OH) D 3 , may posses chemopreventive efficacy in the organs expressing endogenous 1α(OH)ase. In the colon, it has been reported that 1α(OH)ase is present in normal, and malignant colon tumors (3, 4) . Results also showed that high-to moderately differentiated colon tumors express increased 1α(OH)ase, while poorly differentiated tumors consistently have shown reduced expression or complete loss of 1α(OH)ase activity (5) . More recently, we have demonstrated that 1α(OH)ase and VDR are also highly expressed in the pre-cancerous lesions (ACF) of human colon samples (10) . Antiproliferative effects of vitamin D analogs in colon cancer cells have been reported (13) . In this report we evaluated effects of 25(OH)D 3 Expression of 1α-hydroxylase and VDR in human colon tissue. Similar non-nuclear levels of 1α-hydroxylase expression is noted in normal colonic epithelial cells (A), aberrant crypt foci (B), as well as, in well-differentiated tumor cells (C), moderately differentiated tumor cells (D) and poorly differentiated tumor cells (E). VDR expression levels were low in normal colonic epithelial cells (F), increased in aberrant crypt foci (G) with further increase noted in welldifferentiated tumor cells (H). In contrast, moderately differentiated tumor cells (I) appear to have less VDR than the well-differentiated. VDR expression was found to be almost completely lost in poorly differentiated tumor cells (J). Magnification ×1000. 
